2Cummings JL, Doody RC, lark C. Disease modifying therapies for Alzheimer diease: challenges to early intervention[J]. Neurology,2007,69 (16):1622-1634.
3Helznar EP, Luchsinger JA, Scarmeas N,et al. Contribution of vascular risk factors to the progression in Alzheimer disease[J]. Arch Neurol, 2009,66 (3) : 343-348.
9Cutler NR, Sramek JJ. Review of the next generation of Alzheimer's disease therapeutics:challenges for drug development. Prog Neuropsyehopharmaeol Biol Psychiatry,2001,25 ( 1 ) :25.
10Waring SC, Rocca WA, Petersen RC, et al. Postmenopausal replacement therapy and risk of AD : A population based study. Neurology,1999,52(5) :965.
5GARCIA-ALBERCA J M, PABLO LARA J, GONZALEZ-BARON S, et al. Prevalence and comorbidity of neuropsyehiatrie symptoms in Alzheimer's disease [ J ]. Actas Esp Psiquiatr, 2008, 36 (5): 265-270.
6GARCfA - ALBERCA J M, PABLO LARA J, GONZ - LEZ - BARON S, et al. Prevalence and comorbidity of neuropsy- chiatric symptoms in Alzheimer's disease. Actas Esp Psiquiatr,2008,36 (5) :265 - 270.
7Tulloch IF. The pharmacologic selectivity of serotonin re- uptake inhlbitors. European Psychiatry, 1993,8 (Suppl) : 5 S -8S.
